🇺🇸
Seoul, Korea, Aug. 2, 2026 /PRNewswire/ — Mezzion Pharma Co., Ltd. today announced positive results from a new in vivo study of udenafil, a novel phosphodiesterase type 5 (PDE5) inhibitor, in autosomal dominant polycystic kidney disease (ADPKD). In a preclinical ADPKD model, udenafil…
Source: prnewswire
Country: United States